De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: A multicenter non-blinded randomized noninferiority trial.
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Background In patients with severe sepsis, no randomized clinical trial has tested the concept of de-escalation of empirical antimicrobial therapy. This study aimed to compare the de-escalation strategy with the continuation of an appropriate empirical treatment in those patients. Methods This was a multicenter non-blinded randomized noninferiority trial of patients with severe sepsis who were randomly assigned to de-escalation or continuation of empirical antimicrobial treatment. Recruitment began in February 2012 and ended in April 2013 in nine intensive care units (ICUs) in France. Patients with severe sepsis were assigned to de-escalation (n = 59) or continuation of empirical antimicrobial treatment (n = 57). The primary outcome was to measure the duration of ICU stay. We defined a noninferiority margin of 2 days. If the lower boundary of the 95 % confidence interval (CI) for the difference in patients assigned to the de-escalation group was less than 2 days, as compared with that of patients assigned to the continuation group, de-escalation was considered to be noninferior to the continuation strategy. Secondary outcomes included mortality at 90 days, occurrence of organ failure, number of superinfections, and number of days with antibiotics during the ICU stay. Results The median duration of ICU stay was 9 [interquartile range (IQR) 5-22] days in the de-escalation group and 8 [IQR 4-15] days in the continuation group, respectively (P = 0.71). The mean difference was 3.4…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified direct evidence from 13 studies (1968 patients) [277], including 1 RCT [278]. In our meta-analysis, we observed improved short-term mortality in patients who were de-escalated (RR 0.72; 95% CI 0.57–0.91) (Supplementary Appendix 2).”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [278]
Citations
Cites
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510393 · Cited by 3,362
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Hooton, T. M., Bradley, S. F., Cardenas, D. D., Colgan, R., Geerlings, S. E., Rice, J. C., Saint, S., Schaeffer, A. J., Tambayh, P. A., Tenke, P., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/650482 · Cited by 2,099 · cited 10×
“The choice of antibiotics was based on international guidelines [3, 15–18].”
BackgroundMethodInfluentialIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 9×
“The durations of ICU stay were 14 [9–31] days and 15 [8–21] days in the de-escalation group and the continuation group, respectively (P = 0.”
BackgroundInfluentialPractice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602 · cited 10×
“The choice of antibiotics was based on international guidelines [3, 15–18].”
BackgroundMethodInfluentialSolomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
“associated with equivalent or superior clinical outcomes in sepsis and septic shock [54, 190–192]; despite this, at least one study has indicated an increased frequency of superinfection and longer ICU stay [192].”
ResultSurviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
“There was no difference in mortality or ICU length of stay [352].”
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Bloodstream infections in critically ill patients: an expert statement
Timsit, J.-F., Ruppé, E., Barbier, F., Tabah, A., & Bassetti, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05950-6 · Cited by 448
Rationalizing antimicrobial therapy in the ICU: a narrative review
Timsit, J.-F., Bassetti, M., Cremer, O., Daikos, G., de Waele, J., Kallil, A., Kipnis, E., Kollef, M., Laupland, K., Paiva, J.-A., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05520-5 · Cited by 266
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00555-7 · Cited by 224
Tabah, A., Cotta, M. O., Garnacho-Montero, J., Schouten, J., Roberts, J. A., Lipman, J., Tacey, M., Timsit, J.-F., Leone, M., Zahar, J. R., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1199 · Cited by 220
“The other study randomized ADE and a continuation strategy in 120 patients treated with antibiotics for severe sepsis in 9 ICUs [23].”
BackgroundMethodInfluentialBloodstream infections in neutropenic cancer patients: A practical update
Gustinetti, G., & Mikulska, M. (2016) · Virulence · doi:10.1080/21505594.2016.1156821 · Cited by 205
Hospital-acquired pneumonia in ICU
Leone, M., Bouadma, L., Bouhemad, B., Brissaud, O., Dauger, S., Gibot, S., Hraiech, S., Jung, B., Kipnis, E., Launey, Y., et al. (2018) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2017.11.006 · Cited by 199
Sartelli, M., Weber, D. G., Ruppé, E., Bassetti, M., Wright, B. J., Ansaloni, L., Catena, F., Coccolini, F., Abu-Zidan, F. M., Coimbra, R., et al. (2016) · World Journal of Emergency Surgery · doi:10.1186/s13017-016-0089-y · Cited by 197
Tabah, A., Bassetti, M., Kollef, M. H., Zahar, J.-R., Paiva, J.-A., Timsit, J.-F., Roberts, J. A., Schouten, J., Giamarellou, H., Rello, J., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05866-w · Cited by 191
Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams
Weiss, E., Zahar, J.-R., Lesprit, P., Ruppe, E., Leone, M., Chastre, J., Lucet, J.-C., Paugam-Burtz, C., Brun-Buisson, C., Timsit, J.-F., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.03.013 · Cited by 180
Self-citationInitial antimicrobial management of sepsis
Niederman, M. S., Baron, R. M., Bouadma, L., Calandra, T., Daneman, N., DeWaele, J., Kollef, M. H., Lipman, J., & Nair, G. B. (2021) · Critical Care · doi:10.1186/s13054-021-03736-w · Cited by 180
Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria
Bassetti, M., De Waele, J. J., Eggimann, P., Garnacho-Montero, J., Kahlmeter, G., Menichetti, F., Nicolau, D. P., Paiva, J. A., Tumbarello, M., Welte, T., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3719-z · Cited by 181
“suggested [16, 46, 47], de-escalation of antibiotic therapy”
Antimicrobial-associated harm in critical care: a narrative review
Arulkumaran, N., Routledge, M., Schlebusch, S., Lipman, J., & Conway Morris, A. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05929-3 · Cited by 175
Timing of antibiotic therapy in the ICU
Kollef, M. H., Shorr, A. F., Bassetti, M., Timsit, J.-F., Micek, S. T., Michelson, A. P., & Garnacho-Montero, J. (2021) · Critical Care · doi:10.1186/s13054-021-03787-z · Cited by 161
“One multicenter non-blinded trial of ADE compared to continued broad-spectrum therapy did find no difference in mortality but longer length of ICU stay in the ADE arm [44].”
BackgroundKollef, M. H., Bassetti, M., Francois, B., Burnham, J., Dimopoulos, G., Garnacho-Montero, J., Lipman, J., Luyt, C.-E., Nicolau, D. P., Postma, M. J., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4682-7 · Cited by 141
“Despite this basic tenet of antibiotic stewardship, conflicting results have been generated on the overall benefits of antimicrobial de-escalation [12, 13].”
BackgroundShi, Y. P., Huang, Y. X., Zhang, T., Cao, B., Wang, H., Zhuo, C., Ye, F., Su, X., Fan, H. S., Xu, J., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.06.09 · Cited by 159
“after learning the true pathogens (187-189) (IIIC).”
Stevenson, M., Pandor, A., James, M. M., Rafia, R., Uttley, L., Stevens, J., Sanderson, J., Wong, R., Perkins, G. D., McMullan, R., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20460 · Cited by 155
Advances in antibiotic therapy in the critically ill
Vincent, J.-L., Bassetti, M., François, B., Karam, G., Chastre, J., Torres, A., Roberts, J. A., Taccone, F. S., Rello, J., Calandra, T., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1285-6 · Cited by 127
“with de-escalation in various groups of critically ill patients [27–29].”
BackgroundS3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge
Deutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00685-0 · Cited by 148
Waele, J. J. D., Schouten, J. A., Beovič, B., Tabah, A., & Léone, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05871-z · Cited by 130
De Bus, L., Depuydt, P., Steen, J., Dhaese, S., De Smet, K., Tabah, A., Akova, M., Cotta, M. O., De Pascale, G., Dimopoulos, G., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06111-5 · Cited by 114
“The impact of ADE on MDR emergence has been investigated sparsely and no study has found an association between ADE and MDR occurrence in either direction [15, 34, 41, 44].”
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08361-1 · Cited by 141
Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference
Sartelli, M., Catena, F., Abu-Zidan, F. M., Ansaloni, L., Biffl, W. L., Boermeester, M. A., Ceresoli, M., Chiara, O., Coccolini, F., De Waele, J. J., et al. (2017) · World Journal of Emergency Surgery · doi:10.1186/s13017-017-0132-7 · Cited by 199
“However, in 2014, a multicenter randomized trial investigating a strategy based on de-escalation of antibiotics resulted in prolonged duration of ICU stay but did not affect the mortality rate [231].”
BackgroundNishida, O., Ogura, H., Egi, M., Fujishima, S., Hayashi, Y., Iba, T., Imaizumi, H., Inoue, S., Kakihana, Y., Kotani, J., et al. (2018) · Journal of Intensive Care · doi:10.1186/s40560-017-0270-8 · Cited by 118
“The first randomized controlled trial (RCT) enrolling sepsis patients, albeit in a small number, was completed only recently, and as a result, deescalation had no observable impact on either total ICU stay time or 90-day mortality rate [74].”
BackgroundBloodstream infections in the Intensive Care Unit
Bassetti, M., Righi, E., & Carnelutti, A. (2016) · Virulence · doi:10.1080/21505594.2015.1134072 · Cited by 127
Nelson, Z., Aslan, A. T., Beahm, N. P., Blyth, M. D., Cappiello, M., Casaus, D. V., Dominguez, F., Egbert, S., Hanretty, A. M., Khadem, T. M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.44495 · Cited by 142
Albrich, W. C., & Harbarth, S. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3978-8 · Cited by 107
“03) [70].”
An approach to antibiotic treatment in patients with sepsis
Martínez, M. L., Plata-Menchaca, E. P., Ruiz‐Rodríguez, J. C., & Ferrer, R. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.01.47 · Cited by 136
“In this study of 116 patients, the hospital length of stay was significantly longer in the de-escalation group, though it did not affect the mortality rate (100).”
BackgroundWhat’s new in multidrug-resistant pathogens in the ICU?
Zilahi, G., Artigas, A., & Martín‐Loeches, I. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0199-4 · Cited by 118
“[45] conducted a multicenter non-blinded randomized non-inferiority trial of patients with severe sepsis and Garnacho-Montero et al.”
MethodResultPaul, M., Dickstein, Y., & Raz‐Pasteur, A. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.05.023 · Cited by 104
Rapid syndromic molecular testing in pneumonia: The current landscape and future potential
Poole, S., & Clark, T. W. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.11.021 · Cited by 97
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Acute Medicine & Surgery · doi:10.1002/ams2.659 · Cited by 96
Management of severe sepsis: advances, challenges, and current status
Martín‐Loeches, I., Levy, M. M., & Artigas, A. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s78757 · Cited by 102
Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Nishida, O., Ogura, H., Egi, M., Fujishima, S., Hayashi, Y., Iba, T., Imaizumi, H., Inoue, S., Kakihana, Y., Kotani, J., et al. (2018) · Acute Medicine & Surgery · doi:10.1002/ams2.322 · Cited by 85
Bus, L. D., Denys, W., Catteeuw, J., Gadeyne, B., Vermeulen, K., Boelens, J., Claeys, G., Waele, J. J. D., Decruyenaere, J. M. A., & Depuydt, P. O. (2016) · Intensive Care Medicine · doi:10.1007/s00134-016-4301-z · Cited by 85
Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric)
Bretonnière, C., Léone, M., Milési, C., Allaouchiche, B., Armand-Lefèvre, L., Baldési, O., Bouadma, L., Decré, D., Figueiredo, S., Gauzit, R., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3853-7 · Cited by 83
Self-citationGuidelines for Antibiotic Prescription in Intensive Care Unit
Guleria, R., Mohan, A., Kulkarni, A. P., Madan, K., & Hadda, V. (2019) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23101 · Cited by 97
When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit
Denny, K. J., Wale, J. D., Laupland, K. B., Harris, P. N. A., & Lipman, J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.07.007 · Cited by 81
Rieg, S., & Küpper, M. (2016) · Infection · doi:10.1007/s15010-016-0883-1 · Cited by 75
la Martire, G., Robin, C., Oubaya, N., Lepeule, R., Beckerich, F., Leclerc, M., Barhoumi, W., Toma, A., Pautas, C., Maury, S., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3328-1 · Cited by 70
Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance
Liang, S. Y., & Kumar, A. (2015) · Current Infectious Disease Reports · doi:10.1007/s11908-015-0493-6 · Cited by 76
Moreau, A., Martín‐Loeches, I., Póvoa, P. M. S. R., Salluh, J. I., Rodríguez, A. H., Thille, A. W., Díaz, E., Vedes, E., Lobo, S. M., Mégarbane, B., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01656-2017 · Cited by 67
De-escalation of empiric antibiotics in patients with severe sepsis or septic shock: A meta-analysis
Guo, Y., Gao, W. Q., Yang, H., Ma, C., & Sui, S.-J. (2016) · Heart & Lung · doi:10.1016/j.hrtlng.2016.06.001 · Cited by 64
Antibiotic stewardship in the ICU: time to shift into overdrive
Mokrani, D., Chommeloux, J., Pineton de Chambrun, M., Hékimian, G., & Luyt, C.-E. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01134-9 · Cited by 56
“, in their randomized-controlled trial, found similar acquisition of MDR bacteria at day 8 [92].”
BackgroundResultAntibiotic de-escalation in the ICU: how is it best done?
Garnacho-Montero, J., Escoresca-Ortega, A., & Fernández-Delgado, E. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000141 · Cited by 57
Azoulay, E., Guigue, N., Darmon, M., Mokart, D., Lemiale, V., Kouatchet, A., Mayaux, J., Vincent, F., Nyunga, M., Bruneel, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7471 · Cited by 56
“With antibacterial agents, de-escalation has been found feasible and safe in general ICU patients [27, 28] and in ICU patients with neutropenia [29].”
BackgroundIs de-escalation of antimicrobials effective? A systematic review and meta-analysis
Ohji, G., Doi, A., Yamamoto, S., & Iwata, K. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.06.002 · Cited by 66
“Gonzalez et al. conducted a retrospective observational study at a medical ICU in a university hospital in France.37 A variety of infections were included in the analysis and there were no protocols for the administration of empirical antimicrobials.”
MethodInfluentialMontravers, P., Augustin, P., Grall, N., Desmard, M., Allou, N., Marmuse, J.-P., & Guglielminotti, J. (2016) · Critical Care · doi:10.1186/s13054-016-1267-8 · Cited by 55
“demonstrated that de-escalation was inferior to continuation of the initial antibiotic therapy with length of stay as the primary outcome parameter [40].”
BackgroundResultMoraes, R. B., Guillen, J. A. V., Zabaleta, W. J. C., & Borges, F. K. (2016) · Revista Brasileira de Terapia Intensiva · doi:10.5935/0103-507x.20160044 · Cited by 61
Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia
Viasus, D., Simonetti, A. F., García‐Vidal, C., Niubó, J., Dorca, J., & Carratalà, J. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw441 · Cited by 61
Ranzani, O., Senussi, T., Idone, F. A., Ceccato, A., Bassi, G. L., Ferrer, M., & Torres, A. (2019) · Critical Care · doi:10.1186/s13054-019-2348-2 · Cited by 60
De-escalation versus continuation of empirical antimicrobial therapy in community-acquired pneumonia
Yamana, H., Matsui, H., Tagami, T., Hirashima, J., Fushimi, K., & Yasunaga, H. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.07.001 · Cited by 51
De-escalation therapy among bacteraemic patients with community-acquired pneumonia
Carugati, M., Franzetti, F., Wiemken, T. L., Kelly, R., Peyrani, P., Blasi, F., Ramírez, J. A., & Aliberti, S. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.06.015 · Cited by 48
Gustinetti, G., Raiola, A. M., Varaldo, R., Galaverna, F., Gualandi, F., Bono, V. D., Bacigalupo, A. P., Angelucci, E., Viscoli, C., & Mikulska, M. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.03.018 · Cited by 53
Routsi, C., Gkoufa, A., Arvaniti, K., Kokkoris, S., Tourtoglou, A., Theodorou, V., Vemvetsou, A., Kassianidis, G., Amerikanou, A., Paramythiotou, E., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa375 · Cited by 46
Suzuki, A., Maeda, M., Yokoe, T., Hashiguchi, M., Togashi, M., & Ishino, K. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13693 · Cited by 43
Thorndike, J., & Kollef, M. H. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000751 · Cited by 42
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T.-A., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Journal of Intensive Care · doi:10.1186/s40560-025-00776-0 · Cited by 52
Federal guidelines on diagnosis and treatment of community-acquired pneumonia
Avdeev, S. N., Dekhnich, A. V., Zaytsev, A. A., Kozlov, R. S., Rachina, S. A., Руднов, В. А., Sinopalnikov, A. I., Tyurin, I. E., Fesenko, O. V., & Чучалин, А. Г. (2022) · PULMONOLOGIYA · doi:10.18093/0869-0189-2022-32-3-295-355 · Cited by 56
Blood Stream Infections from MDR Bacteria
Franco, S. D., Alfieri, A., Pace, M. C., Sansone, P., Pota, V., Fittipaldi, C., Fiore, M., & Passavanti, M. B. (2021) · Life · doi:10.3390/life11060575 · Cited by 53
“The employment of ADE usually lengthens the duration of antimicrobial therapy [51].”
BackgroundLópez-Cortés, L. E., Delgado-Valverde, M., Moreno-Mellado, E., Goikoetxea Aguirre, J., Guio Carrión, L., Blanco Vidal, M. J., López Soria, L. M., Pérez-Rodríguez, M. T., Martínez Lamas, L., Arnaiz de las Revillas, F., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00686-2 · Cited by 38
Antimicrobial Therapy and Antimicrobial Stewardship in Sepsis
Seok, H., Jeon, J. H., & Park, D. W. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.1.19 · Cited by 51
“In previous ADE studies conducted with ICU patients as endpoints for MDRO acquisition, there was no significant association between ADE and MDRO acquisition [37, 42, 43].”
MethodResultThe Burden of Sepsis and Septic Shock in the Intensive Care Unit
Via, L. L., Maniaci, A., Lentini, M., Cuttone, G., Ronsivalle, S., Tutino, S., Rubulotta, F. M., Nunnari, G., & Marıno, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196691 · Cited by 62
“Antimicrobial de-escalation, based on culture results and clinical trajectory, is critical to reduce selective pressure and prevent Clostridioides difficile infection [58].”
Arulkumaran, N., Khpal, M., Tam, K., Baheerathan, A., Corredor, C., & Singer, M. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004267 · Cited by 36
Bakterielle Sepsis: Diagnostik und kalkulierte Antibiotikatherapie
Richter, D., Heininger, A., Brenner, T., Hochreiter, M., Bernhard, M., Briegel, J., Dubler, S., Grabein, B., Hecker, A., Krüger, W. A., et al. (2017) · Der Anaesthesist · doi:10.1007/s00101-017-0363-8 · Cited by 37
De-escalation as a potential way of reducing antibiotic use and antimicrobial resistance in ICU
Timsit, J., Harbarth, S., & Carlet, J. M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3485-3 · Cited by 35
“[17] reported a randomized controlled trial (RCT) evaluating the impact of antibiotic treatment de-escalation.”
BackgroundMadaras‐Kelly, K., Jones, M., Remington, R. E., Caplinger, C., Huttner, B. D., Jones, B. E., & Samore, M. H. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv338 · Cited by 36
Efficacy and safety of antimicrobial de-escalation as a clinical strategy
Mathieu, C., Pastène, B., Cassir, N., Martín‐Loeches, I., & Léone, M. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1561275 · Cited by 41
“Three studies reported superinfection rates [11,21,22].”
BackgroundResultInfluentialAntimicrobial De-Escalation in the ICU: From Recommendations to Level of Evidence
Lakbar, I., Waele, J. J. D., Tabah, A., Einav, S., Martín‐Loeches, I., & Léone, M. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01390-2 · Cited by 43
“At this time three RCTs are ongoing on this topic.”
BackgroundThe use and risks of antibiotics in critically ill patients
Denny, K. J., Cotta, M. O., Parker, S. L., Roberts, J. A., & Lipman, J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1164690 · Cited by 34
“[54,55] In a multicenter, nonblinded, randomized noninferiority”
BackgroundSieswerda, E., Bax, H. I., Hoogerwerf, J. J., de Boer, M. G. J., Boermeester, M. A., Bonten, M. J. M., Dekker, D., van Wijk, R. G., Juffermans, N. P., Kuindersma, M., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07653-3 · Cited by 36
Beyond Antimicrobial Use: A Framework for Prioritizing Antimicrobial Resistance Interventions
Noyes, N. R., Slizovskiy, I. B., & Singer, R. S. (2021) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-072020-080638 · Cited by 37
Antibiotic therapy for severe bacterial infections
Timsit, J., Ling, L., de Montmollin, É., Bracht, H., Morris, A. C., Bus, L. D., Falcone, M., Harris, P. N. A., Machado, F. R., Paiva, J.-A., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08063-0 · Cited by 47
Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU
Bassetti, M., Poulakou, G., & Timsit, J. (2016) · Intensive Care Medicine · doi:10.1007/s00134-016-4341-4 · Cited by 31
Deutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00671-6 · Cited by 37
Kam, K. Q., Chen, T., Kadri, S. S., Lawandi, A., Yek, C., Walker, M., Warner, S., Fram, D., Chen, H.-C., Shappell, C. N., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae591 · Cited by 29
Sepsis in the critically ill patient: current and emerging management strategies
Heming, N., Azabou, É., Cazaumayou, X., Moine, P., & Annane, D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1846522 · Cited by 36
“Antimicrobial de-escalation appears to be safe [20], but may be associated with increased length of ICU stay [21].”
BackgroundAvdeev, S. N., Борисович, Б. В., Belotserkovskiy, B. Z., Gritsan, A. I., Dekhnich, A. V., Zaytsev, A. A., Кirov, М. Y., Kozlov, R. S., Владимирович, К. В., Николаевич, П. Д., et al. (2022) · Russian Journal of Anesthesiology and Reanimatology · doi:10.17116/anaesthesiology20220116 · Cited by 37
S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Update 2025
Brunkhorst, F. M., Adamzik, M., Axer, H., Bauer, M. W., Bode, C., Bone, H.-G., Brenner, T., Bucher, M., David, S., Dietrich, M., et al. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01317-1 · Cited by 47
Moniz, P., Coelho, L., & Póvoa, P. M. S. R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01558-w · Cited by 38
Alshareef, H. M., Alfahad, W. A., Albaadani, A., Alyazid, H., & Talib, R. B. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.03.004 · Cited by 34
Foucrier, A., Dessalle, T., Tuffet, S., Federici, L., Dahyot‐Fizelier, C., Barbier, F., Pottecher, J., Monsel, A., Hissem, T., Lefrant, J., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04457-y · Cited by 37
“The ICU length of stay in patients who received a combination of antibiotics for definitive antibiotic therapy was 38 [25.0; 60.0] days for combination therapy, compared with 33 [21.0; 51.0] days for monotherapy ( P = 0.065) (Table 2).”
ResultInfluentialSelf-citationRattanaumpawan, P., Werarak, P., Jitmuang, A., Kiratisin, P., & Thamlikitkul, V. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2284-1 · Cited by 26
Timsit, J., Perner, A., Bakker, J., Bassetti, M., Benoît, D., Cecconi, M., Curtis, J. R., Doig, G. S., Herridge, M. S., Jaber, S., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3755-8 · Cited by 29
“[35] in their multicenter, non-blinded, randomized noninferiority trial included patients with severe sepsis that were randomly assigned to de-escalation or continuation of empirical antimicrobial treatment.”
BackgroundSelf-citationPneumonies associées aux soins de réanimation
Léone, M., Bouadma, L., Bouhemad, B., Brissaud, O., Dauger, S., Gibot, S., Hraiech, S., Jung, B., Kipnis, É., Launey, Y., et al. (2018) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2018.07.003 · Cited by 41
Antibiotic use in critical illness
Stewart, S. D., & Allen, S. J. (2019) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12842 · Cited by 26
Yoshida, H., Motohashi, T., Bus, L. D., Waele, J. J. D., Takaba, A., Kuriyama, A., Kobayashi, A., Tanaka, C., Hashi, H., Hashimoto, H., et al. (2022) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-022-01146-3 · Cited by 26
“One small non-blinded randomized controlled trial found that de-escalation programs had the potential to worsen patient prognosis [13], even though the incidence of Clostridioides difficile infection might be reduced by early de-escalation of antipseudomonal β-lactams [14].”
BackgroundAntimicrobial De-Escalation in Critically Ill Patients
Tanzarella, E. S., Cutuli, S. L., Lombardi, G., Cammarota, F., Caroli, A., Franchini, E. O., Sancho, E., Grieco, D. L., Antonelli, M. M., & PASCALE, G. D. (2024) · Antibiotics · doi:10.3390/antibiotics13040375 · Cited by 32
“Likewise, no difference was observed in terms of the selection of MDR pathogens between ADE and non-ADE groups (23.5 vs. 18.6, respectively, p = 0.35), which is in agreement with previous investigations [15–17].”
ResultInfluentialCarlier, M., Roberts, J. A., Stove, V. V., Verstraete, A., Lipman, J., & Waele, J. J. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00409-15 · Cited by 21
Gutiérrez-Pizarraya, A., Léone, M., Garnacho‐Montero, J., Martin, C., & Martín‐Loeches, I. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1293520 · Cited by 25
“mannii, Pseudomonas aeruginosa, and Enterobacter species) were considered ‘difficult-to-treat infections’ [10].”
BackgroundMethodInfluentialSelf-citationUnmet needs in the management of intra-abdominal infections
Montravers, P., Tashk, P., & Tran‐Dinh, A. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1372750 · Cited by 20
“In a trial studying ICU patients randomly assigned to de-escalation or continuation of empiric therapy, the authors reported that de-escalation did not modify the survival rate but was associated with longer ICU stay [77].”
BackgroundCarrié, C., Bardonneau, G., Petit, L., Ouattara, A., Gruson, D., Pereira, B., & Biais, M. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.11.005 · Cited by 19
Dong, M., Wang, J., Wu, Y., Chen, B., Yu, M., & Wen, A. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.06.025 · Cited by 19
Salahuddin, N., Amer, L. G., Joseph, M., Elhazmi, A., Hawa, H., & Maghrabi, K. A. (2016) · Critical Care Research and Practice · doi:10.1155/2016/6794861 · Cited by 21
“, 2014 [15] Multicenter, RCT Severe sepsis 60 — Deescalation resulted in prolonged duration of ICU stay; mean difference 3.”
Background
Metadata
- Authors
- Leone, M., Bechis, C., Baumstarck, K., Lefrant, J.-Y., Albanèse, J., Jaber, S., Lepape, A., Constantin, J.-M., Papazian, L., Bruder, N., Allaouchiche, B., Bézulier, K., Antonini, F., Textoris, J., Martin, C., & For the AZUREA Network Investigators
- Affiliations
- Hôpital Nord (FR)
- Aix-Marseille Université (FR)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Hôpital de la Conception (FR)
- Inserm (FR)
- Hospices Civils de Lyon (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Centre National de la Recherche Scientifique (FR)
- Hôpital de la Timone (FR)
- ORCID
- Venue
- Intensive Care Medicine
- Published
- 2014-08-05
- Volume
- 40
- Issue
- 10
- Pages
- 1399-1408
- ISSN
- 0342-4642 (ISSN-L)
- 1432-1238
- OpenAlex
- W2053430308
- Cited by
- 243
- References
- 32
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 18 · 2023: 18 · 2022: 17 · 2021: 18 · 2020: 28 · 2019: 27 · 2018: 18 · 2017: 22 · 2016: 32 · 2015: 14 · 2014: 5
- FWCI
- 18.32
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-10-07)
- Open access
- green
- hal.umontpellier.fr
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Intensive Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- severe sepsis, antibiotic de-escalation, empirical antimicrobial therapy, ICU length of stay, superinfection, antibiotic duration, mortality, organ failure
- MeSH terms
- Aged, Anti-Bacterial Agents, Female, France, Humans, Intensive Care Units, Length of Stay, Male, Microbial Sensitivity Tests, Middle Aged, Multivariate Analysis, Linear Models, Proportional Hazards Models, Sepsis, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.